Figure 3.
(A) Daytime asthma symptom frequency (baseline through 12 mo); shown are the reductions in daytime symptoms for each group (P < 0.0001). (B) Nocturnal asthma symptom frequency (baseline through 12 mo); shown are the reductions in nocturnal symptoms for each group (P < 0.0001). (C) Frequency of β-agonist use (baseline through 12 mo); shown are the reductions in β-agonist use for each group (P < 0.0001). WAAP = written asthma action plan.